Analysis of the course and outcomes of COVID-19 in HIV infected patients according to the infectious diseases’ hospital of Moscow

The course of two pandemics (syndemic) — HIV & COVID-19, demonstrated the synergistic eff ect of SARS-CoV-2 & HIV on the human body.

The aim of the study was to identify the features of diagnosis, course, treatment and outcomes of coronavirus infection (COVID-19) in HIV infected patients admitted to an infectious hospital.

Materials and methods: the retrospective data of 1,250 patients with COVID-19/HIV coinfection admitted to ICH No. 2 in Moscow in 2021 have been analyzed. Laboratory and instrumental diagnostics were carried out to clarify the diagnosis and severity of the condition. Statistical processing was performed using Excel (Microsoft) and StatTech v. 1.2.0 software. The diff erences were considered statistically signifi cant at p <0.05.

The results of the conducted studies of 1,250 patients with coinfection have shown that HIV infection does not aff ect the risk of contracting SARS-CoV-2, and at the same time, the key predictors that cause high mortality in COVID-19 against the background of HIV infection are age over 55, avoidance of regular checkups and antiretroviral therapy (ART), severe immunodefi ciency (CD4+ < 200 μl^–1), concomitant pathology (HCV, liver cirrhosis, damage to the cardiovascular system) and a combination of SARS-CoV-2 with various opportunistic pathogens. Late diagnosis of HIV infection contributes to a more severe course and unfavorable outcome of COVID-19 in HIV infected patients in the future. Counting the potential cost and benefi ts for each individual patient has proved that the use of biological therapy in patients with coinfection is recommended only after monitoring the immunological status indicators. Benefi cial eff ect factors in relation to HIV/SARS-CoV-2 coinfection include vaccination of HIV infected patients against COVID-19, which shows the greatest eff ectiveness in people receiving ART, with the amount of CD4+ ≥ 350 μl^–1, thus preventing infection, reducing the risk of severe disease and the frequency of hospitalization and mortality rate.

1. URL:http://government.ru/docs/all/126028/ (In Russian)]. [Electronic resource]. URL: https://www.worldometers.info/coronavirus/

2. Odone A., Delmonte D., Scognamiglio T., Signorelli C. COVID-19 deaths in Lombardy, Italy: data in context. Lancet Public Heal. 2020;5(6):e310

3. Mazus A.I., Nagibina M.V., Bessarab T.P. et al. COVID-19/HIV co-infection: characteristics of patients of the Moscow megalopolis. Therapy. 2021;4(46):18–24. (In Russian)]. DOI: 10.18565/therapy.2021.4.18-24 [Electronic resource]. URL: https://www.ecdc.europa.eu/en/publications-data/hiv-aids-surveillance-europe-2021-2020-data

4. Etienne N., Karmochkine M., Slama L. et al. HIV infection and COVID-19: risk factors for severe disease. AIDS. 2020;34(12):1771–74. DOI: 10.1097/QAD.0000000000002651

5. Ermilov V.V., Smirnov A.V., Dorofeev N.A. et al. COVID-19 in young patients with comorbid pathology on the background of immunosuppression (a case from practice). Bulletin of the Volgograd State Medical University. 2021;1(77):84–88. (In Russian)]. DOI 10.19163/1994-9480-2021-1(77)-84-88

6. Inciartea A., Gonzalez-Cordona A. et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS. 2020;34:1775–1780. DOI: 10.1097/QAD.0000000000002643

7. Yuki K., Fujiogi M., Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin. Immunol. 2020;215:108427. DOI: 10.1016/j.clim.2020.108427

8. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020;28;71(15):762–768. DOI: 10.1093/cid/ciaa248

9. Hsi-en Ho, Michael J.P. et al. Clinical outcomes and immunologic characteristics of coronavirus disease 2019 in People With Human Immunodefi ciency Virus. J. Infect. Dis. 2021;223(3):403–408. DOI: 10.1093/infdis/jiaa380

10. Cevik M., Bamford C.G.G., Ho A. COVID-19 pandemic: a focused review for clinicians. Clin. Microbiol. Infect. 2020;26(7):842–47. DOI: 10.1016/j.cmi.2020.04.023

11. Carr E., Bendayan R., Bean D. et al. Evaluation and improvement of the National Early Warning Score (NEWS2) for COVID-19: a multihospital study. BMC Med. 2021;19(1):23. DOI: 10.1186/s12916-020-01893-3

12. Vizcarra P., Pérez-Elías M.J., Quereda C. et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020;7(8):e554–64. DOI: 10.1016/S2352-3018(20)30164-8

13. Shoaib N., Noureen N., Munir R. et al. COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. PLoS ONE. 2021;16(8):e0255999. DOI: 10.1371/journal.pone.0255999

14. Wang L. C-reactive protein levels in the early stage of COVID-19. Med. Mal. Infect. 2020;50(4):332–334. DOI: 10.1016/j.medmal.2020.03.007

15. Nomah D.K., Reyes-Urueña J., Llibre J.M. et al. HIV and SARSCoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. Curr. HIV/AIDS Rep. 2021;18(6):518–526. DOI: 10.1007/s11904-021-00579-6

16. Henderson M., Fidler S., Mothe B. et al. Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. J. Int. AIDS Soc. 2022;25(2):e25882. DOI: 10.1002/jia2.25882 [Electronic resource]. URL: https://cr.minzdrav.gov.ru/recomend/791

17. Byrd K.M., Beckwith C.G., Garland J.M. et al. SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. J. Int AIDS Soc. 2020;23(7):e25573. DOI: 10.1002/jia2.25573

18. Nechaeva O.B. Socially signifi cant infectious diseases that pose a biological threat to the population of Russia. Tuberculosis and Lung Diseases. 2019;97(11):7–17. (In Russian)]. DOI: 10.21292/2075-1230-2019-97-11-7-17

19. Mazus A.I., Tsyganova E.V., Gushchin V.A. et al. Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy. Lancet. 2022;46. DOI: 10.1016/j.eclinm.2022.101360